Viiv Healthcare

This study tests if adults with HIV who have their virus under control can switch from daily pills to a monthly injection. About 631 participants will either stay on their current pills or switch to the shots. The goal is to see if the shots work just as well at keeping the virus…

This early-stage study tests a new lab-made antibody called VH4527079 in healthy adults and people with HIV. The goal is to check if it is safe and how the body processes it when given as a shot or IV. About 102 participants will receive one or more doses. This is not a cure; it …

This study tested whether adults with HIV whose virus is already suppressed by daily pills can switch to a monthly injection of two long-acting drugs (cabotegravir and rilpivirine) and keep the virus under control. About 618 participants were randomly assigned to either stay on t…

This study tests whether a two-drug HIV pill (dolutegravir/lamivudine) works as well as a three-drug pill (bictegravir/emtricitabine/tenofovir alafenamide) for adults who have never taken HIV medication before. About 473 participants will take one of the two daily pills for up to…

This early-phase study tests whether adding an experimental drug (VH3810109) with or without another drug (fostemsavir) to standard HIV therapy can reduce the amount of hidden HIV in the body. About 107 adults with HIV, both newly diagnosed and those already on treatment, will ta…

This study tests a new drug, VH3810109, given with another HIV medicine (cabotegravir) in adults whose HIV is already well-controlled. The goal is to see if this combination can keep the virus suppressed as well as standard treatments. About 185 participants will receive the drug…

This study looks at two different HIV treatments for people who have never taken HIV medication before. Everyone starts with a daily pill (Dolutegravir/Lamivudine) to lower the virus to undetectable levels. Once that happens, participants can choose to either stay on the daily pi…

This study tests a new version of the HIV prevention drug cabotegravir, given as a shot every 4 months. About 229 teens and adults at risk of HIV will receive the injection to see if it keeps drug levels high enough to prevent infection. The goal is to make HIV prevention easier …

This early-stage study is testing the safety and tolerability of an experimental HIV treatment called a capsid inhibitor. It involves 85 healthy adults who receive one or more injections of the drug or a placebo. The goal is to see how the body handles the drug and whether it cau…

This study looks at how healthy adults without HIV tolerate two long-acting injections used to prevent or treat HIV. About 65 participants will receive both shots at different times to compare injection site reactions and overall acceptability. The goal is to understand if people…